Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation

Save

Secukinumab in patients with Psoriatic Arthritis and Axial Manifestation: results from the double-blind, randomised, phase 3 MAXIMISE trial.

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Save

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.

The Role of a Selective IL-23 p19 inhibitor for Patients with Psoriatic Arthritis

Save

Psoriatic arthritis is heterogeneous in symptoms and severity. A selective IL-23 p19 inhibitor with a 12-week maintenance dosing interval is approved for adults with active PsA

Long-Term Safety Profile of Secukinumab: Analysis of Malignancies Up to 5 Years of Exposure Across Indications

Save

The risk of malignancy in secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis patients: analysis of up to five-year clinical trial and postmarketing surveillance data with up to five years of follow-up.

Comorbidities in axSpA: A Focus on Cardiovascular Features

Save

Patients with axial spondyloarthritis (axSpA) commonly experience cardiovascular (CV) comorbidities. There is a need to holistically assess a patient, including considerations for managing disease activity and understanding the safety profile of available therapies as it relates to comorbidities. Join Marina Magrey, MD as she provides insight on this topic for holistic patient-centered care.

Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-Related Arthritis (ERA): Current Challenges and Future Outlook

Save

There is a significant burden of disease associated with JPsA and ERA, with patients experiencing structural damage progression, risk of disability, and comorbidities that may persist into adulthood. This presentation led by Hermine Brunner, MD educates on the importance of early recognition and management.

Women Leaders in Rheumatology: Leadership in a Virtual World

Save

A moderated panel of prominent female rheumatologists will discuss the challenges and successes in clinical practice and research that they encountered during the COVID-19 pandemic.

Expert-Selected EULAR 2021 Abstracts

Save

Didn’t have time to join EULAR 2021? Listen to a panel of experts as they present their views on the key abstracts in SpA and Still’s disease.

Expert Perspectives on Lupus Nephritis

Save

In this disease education video series from GSK, leading rheumatologists and nephrologists share their perspectives on lupus nephritis and reflect upon the gaps that remain in our understanding and management of the disease.

Axial Involvement in Spondyloarthritis: A Patient-Centered Exploration

Save

Listen to Ethan Craig, MD, MPH discuss 3 of his patient cases to identify and differentiate axial involvement within the spectrum of spondyloarthritis.

The Reflecting Rheum: 2020 SpA and Still’s Disease Highlights

Save

Listen to a discussion of medical experts share their views on the most impactful work done in Spondyloarthritis and Still’s Disease in 2020.